Merck stock rallies after U.S. plans to buy 1.4 million more COVID-19 pill courses for $1 billion if authorized
Marketwatch -

Shares of Merck & Co. Inc. rallied 1.9% in premarket trading Tuesday, after the drug maker and partner Ridgeback Biotherapeutics said the U.S. government will exercise options to buy 1.4 million additional courses of the companies' antiviral pill molnupiravir for $1 billion if the COVID-19 treatment is either granted Emergency Use Authorization or approved by the Food and Drug Administration. That brings the total commitment from the U.S. government to 3.1 million course of molnupiravir for...

Read this story at

Loading...

Related Articles